Literature DB >> 28968061

Comparative in Vivo Investigation of Intrathecal and Intracerebroventricular Administration with Melanocortin Ligands MTII and AGRP into Mice.

Danielle N Adank1, Mary M Lunzer1, Cody J Lensing1, Stacey L Wilber1, Amy M Gancarz2, Carrie Haskell-Luevano1.   

Abstract

Central administration of melanocortin ligands has been used as a critical technique to study energy homeostasis. While intracerebroventricular (ICV) injection is the most commonly used method during these investigations, intrathecal (IT) injection can be equally efficacious for the central delivery of ligands. Importantly, intrathecal administration can optimize exploration of melanocortin receptors in the spinal cord. Herein, we investigate comparative IT and ICV administration of two melanocortin ligands, the synthetic MTII (Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2) MC4R agonist and agouti-related peptide [AGRP(87-132)] MC4R inverse agonist/antagonist, on the same batch of age-matched mice in TSE metabolic cages undergoing a nocturnal satiated paradigm. To our knowledge, this is the first study to test how central administration of these ligands directly to the spinal cord affects energy homeostasis. Results showed, as expected, that MTII IT administration caused a decrease in food and water intake and an overall negative energy balance without affecting activity. As anticipated, IT administration of AGRP caused weight gain, increase of food/water intake, and increase respiratory exchange ratio (RER). Unexpectantly, the prolonged activity of AGRP was notably shorter (2 days) compared to mice given ICV injections of the same concentrations in previous studies (7 days or more).1-4 It appears that IT administration results in a more sensitive response that may be a good approach for testing synthetic compound potency values ranging in nanomolar to high micromolar in vitro EC50 values. Indeed, our investigation reveals that the spine influences a different melanocortin response compared to the brain for the AGRP ligand. This study indicates that IT administration can be a useful technique for future metabolic studies using melanocortin ligands and highlights the importance of exploring the role of melanocortin receptors in the spinal cord.

Entities:  

Keywords:  AGRP; ICV; IT; MTII; obesity

Mesh:

Substances:

Year:  2017        PMID: 28968061      PMCID: PMC5821609          DOI: 10.1021/acschemneuro.7b00330

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  32 in total

1.  Endogenous and exogenous melanocortin antagonists induce anti-allodynic effects in a model of rat neuropathic pain.

Authors:  Rosalia Bertorelli; Silva Fredduzzi; Glauco Tarozzo; Marilena Campanella; Robert Grundy; Massimiliano Beltramo; Angelo Reggiani
Journal:  Behav Brain Res       Date:  2005-02-10       Impact factor: 3.332

2.  Long-term orexigenic effects of AgRP-(83---132) involve mechanisms other than melanocortin receptor blockade.

Authors:  M M Hagan; P A Rushing; L M Pritchard; M W Schwartz; A M Strack; L H Van Der Ploeg; S C Woods; R J Seeley
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-07       Impact factor: 3.619

3.  Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity.

Authors:  Dominique D Pierroz; Mary Ziotopoulou; Linda Ungsunan; Stergios Moschos; Jeffrey S Flier; Christos S Mantzoros
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

4.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2016-03-29       Impact factor: 7.446

5.  Effects of stress on dietary preference and intake are dependent on access and stress sensitivity.

Authors:  Sarah L Teegarden; Tracy L Bale
Journal:  Physiol Behav       Date:  2007-11-28

6.  Melanocortin receptor agonists and antagonists modulate nociceptive sensitivity in the mouse formalin test.

Authors:  Sara Bellasio; Elisa Nicolussi; Rosalia Bertorelli; Angelo Reggiani
Journal:  Eur J Pharmacol       Date:  2003-12-15       Impact factor: 4.432

7.  Exploration of Energy Metabolism in the Mouse Using Indirect Calorimetry: Measurement of Daily Energy Expenditure (DEE) and Basal Metabolic Rate (BMR).

Authors:  Carola W Meyer; Peter Reitmeir; Matthias H Tschöp
Journal:  Curr Protoc Mouse Biol       Date:  2015-09-01

8.  Melanocortin 4 receptor is expressed in the dorsal root ganglions and down-regulated in neuropathic rats.

Authors:  Katarzyna Starowicz; Wiktor Bilecki; Agnieszka Sieja; Barbara Przewlocka; Ryszard Przewlocki
Journal:  Neurosci Lett       Date:  2004-03-25       Impact factor: 3.046

9.  Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter.

Authors:  Hongyan Liu; Toshiro Kishi; Aaron G Roseberry; Xiaoli Cai; Charlotte E Lee; Jason M Montez; Jeffrey M Friedman; Joel K Elmquist
Journal:  J Neurosci       Date:  2003-08-06       Impact factor: 6.167

10.  Measuring energy metabolism in the mouse - theoretical, practical, and analytical considerations.

Authors:  John R Speakman
Journal:  Front Physiol       Date:  2013-03-14       Impact factor: 4.566

View more
  7 in total

1.  Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice.

Authors:  Katlyn A Fleming; Mark D Ericson; Katie T Freeman; Danielle N Adank; Mary M Lunzer; Stacey L Wilber; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-02-13       Impact factor: 4.418

2.  Incorporation of Agouti-Related Protein (AgRP) Human Single Nucleotide Polymorphisms (SNPs) in the AgRP-Derived Macrocyclic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-dPro] Decreases Melanocortin-4 Receptor Antagonist Potency and Results in the Discovery of Melanocortin-5 Receptor Antagonists.

Authors:  Zoe M Koerperich; Mark D Ericson; Katie T Freeman; Robert C Speth; Irina D Pogozheva; Henry I Mosberg; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2020-01-06       Impact factor: 7.446

3.  Comparative Intracerebroventricular and Intrathecal Administration of a Nanomolar Macrocyclic Melanocortin Receptor Agonist MDE6-5-2c (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro]) Decreases Food Intake in Mice.

Authors:  Danielle N Adank; Mary M Lunzer; Mark D Ericson; Zoe M Koeperich; Stacey L Wilber; Katlyn A Fleming; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2020-09-10       Impact factor: 4.418

4.  Functional Mixture-Based Positional Scan Identifies a Library of Antagonist Tetrapeptide Sequences (LAtTeS) with Nanomolar Potency for the Melanocortin-4 Receptor and Equipotent with the Endogenous AGRP(86-132) Antagonist.

Authors:  Mark D Ericson; Skye R Doering; Courtney M Larson; Katie T Freeman; Travis M LaVoi; Haley M Donow; Radleigh G Santos; Rachel H Cho; Zoe M Koerperich; Marc A Giulianotti; Clemencia Pinilla; Richard A Houghten; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2021-09-30       Impact factor: 8.039

5.  Synergistic Multiresidue Substitutions of a Macrocyclic c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-dPro] Agouti-Related Protein (AGRP) Scaffold Yield Potent and >600-Fold MC4R versus MC3R Selective Melanocortin Receptor Antagonists.

Authors:  Katlyn A Fleming; Katie T Freeman; Mark D Ericson; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2018-08-16       Impact factor: 7.446

Review 6.  A Review of Single-Nucleotide Polymorphisms in Orexigenic Neuropeptides Targeting G Protein-Coupled Receptors.

Authors:  Mark D Ericson; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-05-11       Impact factor: 4.418

7.  Effects of intrathecal and intracerebroventricular microinjection of kaempferol on pain: possible mechanisms of action.

Authors:  Sajjad Jabbari; Maryam Bananej; Mohammad Zarei; Alireza Komaki; Ramin Hajikhani
Journal:  Res Pharm Sci       Date:  2021-03-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.